- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05862727
Preschool Attention and Sleep Support (PASS) (PASS)
February 2, 2026 updated by: Duke University
Preschool Attention and Sleep Support (PASS): A Telehealth Intervention for Children at Risk for ADHD
This study will be investigating two telehealth interventions for preschoolers with ADHD.
The study is divided into two Aims.
During Aim 1, caregivers of preschoolers with attention concerns, pediatric behavioral health professionals, and pediatric primary care providers will take part in two virtual focus groups to provide their perspective on ways to improve the telehealth intervention being evaluated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
During Aim 2, caregivers of preschool children with ADHD symptoms will be randomly assigned to participate in one of two 9-week telehealth interventions.
Both interventions will teach evidence-based skills and provide practice opportunities to manage their children's ADHD-related behaviors.
Caregivers and their children will also attend three study visits (one before the intervention, and two following the intervention) where they will be asked to complete questionnaires and assessments related to the child's ADHD symptoms, psychiatric health, and sleep habits.
Following each study visit, participating children will be asked to wear an ActiGraph device on their nondominant wrist for 24 hours/day for a 7-day period.
During this time, the caregivers will be asked to complete an electronic daily diary about their child's sleep.
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- child must be ages 3-5 years at intake
- child with score of 30 on the Child Sleep Habits Survey-Short Form and a caregiver rating of child's sleep problems as moderate/severe
- child with ≥80th percentile on the clinician-rated ADHD-RS based on age and sex norms, with at least 4 symptoms in the clinically significant range (scores of 2-3) in either the inattention or hyperactive/impulsive domains
- parent/caregiver must have ability to speak, read, and write in English
- parent/caregiver must have access to a device with internet and/or smartphone to access telehealth visits
- parent/caregiver must have ability to follow written and verbal instructions
- parent/caregiver must have ability and willingness to comply with study procedures.
Exclusion Criteria:
- child with suspected obstructive sleep apnea or restless legs syndrome (via screening questionnaires)
- child with current use of stimulant medication, other psychotropics, or medications for sleep (prescription or over-the-counter, including melatonin)
- child with caregiver report of psychiatric disorder other than ADHD requiring treatment (medication and/or therapy), Autism Spectrum Disorder, or intellectual disability
- parent/caregiver is currently participating in another parent training intervention or have previously participated in another parent training intervention in the past 6 months.
- Severe and/or uncontrolled medical condition (e.g., pulmonary and neurological conditions such as cystic fibrosis and seizure disorder) that would interfere with sleep and/or study participation according to the study team
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PASS Arm1
Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, such as establishing daytime and bedtime routines, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.
|
Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
|
|
Active Comparator: PASS Arm2
Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, including in home and public settings, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.
|
Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in clinician-rated ADHD-RS
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A clinician-rated, 18-item assessment with a 4-point Likert scale ranging from Rarely or never to Very Often. Lower scores indicate better outcomes. |
Baseline, immediately post-treatment, 3 months post-treatment
|
|
Change in caregiver-reported sleep habits as measured by the Short-Form Child Sleep Habits Questionnaire (SF-CSHQ).
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A 23-item questionnaire with a 3-point Likert scale ranging from Rarely to Usually.
Lower scores indicate better outcomes.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
|
Change in Sleep Regularity Index (SRI)
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A measure of sleep regularity collected continuously over 7 days via Actigraphy.
The SRI is calculated as the proportion of pairs of time points 24 hours apart that have matching sleep/wake status
|
Baseline, immediately post-treatment, 3 months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in psychosocial function as measured by Impairment Rating Scale
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A clinician rated, 8-item assessment with a 7-point Likert scale ranging from No problem; definitely does not need treatment/special services to Extreme Problem; definitely needs treatment/special services.
Lower scores indicate better outcomes.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
|
Change in parenting stress as measured by the Parenting Stress Scale
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
An 18-item questionnaire with a 5-point Likert Scale ranging from Strongly disagree to Strongly Agree.
Lower scores indicate better outcomes.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
|
Change in comorbid symptoms as measured by Child Behavioral Checklist for Ages 1½ to 5(CBCL)
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A widely-used 99-item parent report questionnaire with a 3-point Likert Scale ranging from Not True to Very True or Often True.
Lower scores indicate better outcomes.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
|
Change in sleep midpoint, TST (minutes from sleep start to sleep end), SOL (minutes to first sleep epoch), WASO (minutes awake between sleep start and sleep end), and SE (TST/time in bed).
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
As measured via actigraphy collected continuously over 7 days.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
|
Change in parenting style as measured by the Alabama Parenting Questionnaire
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A 33-item questionnaire with a 5-point Likert Scale ranging from Never to Always.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
|
Change in severity of behavior problems in the home setting as measured by the Home Situations Questionnaires.
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A 16-item questionnaire with a 9-point Likert Scale.
Lower scores indicate better outcomes.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Recruitment
Time Frame: Baseline
|
The percentage of enrolled participants who attend a screening visit.
|
Baseline
|
|
Feasibility of Randomization
Time Frame: Baseline
|
The percent of randomized participants who meet study eligibility after attending the screening visit.
|
Baseline
|
|
Integrity of the control condition as measured by the Integrity of the Blind questionnaire.
Time Frame: immediately post-treatment
|
Asking all blinded informant (parents, assessors) to guess whether the child was in the control or experimental group and to state their confidence in this guess on a 1 to 10 scale.
Higher scores indicate higher confidence in guess.
|
immediately post-treatment
|
|
Retention
Time Frame: Immediately post-treatment, 3 months post-treatment
|
Measured by the number of families who complete post-treatment and follow-up assessments.
|
Immediately post-treatment, 3 months post-treatment
|
|
Acceptability as measured by the Satisfaction with Therapy and Therapist Scale (STTS-R).
Time Frame: Immediately post-treatment
|
A 13-item questionnaire with a 5-point Likert Scale ranging from Strongly Disagree (1) to Strongly Agree (5).
Higher scores indicate better outcomes.
|
Immediately post-treatment
|
|
Treatment Fidelity
Time Frame: During the 9-week treatment
|
The percentage of content and practices of the PASS protocol that were delivered (yes/no) across providers as determined by rater's assessment of recorded sessions.
|
During the 9-week treatment
|
|
Integrity of the control condition as measured by the PASS Fidelity Checklist.
Time Frame: During the 9-week treatment
|
The incidence of administration of core PASS elements in each session of the control group determined by rater.
|
During the 9-week treatment
|
|
Index of treatment engagement as measured by attendance.
Time Frame: During the 9-week treatment
|
Average number PASS groups sessions attended by participants.
|
During the 9-week treatment
|
|
Adherence to between-session practice.
Time Frame: During the 9-week treatment
|
Assessed via a therapist-completed item assessing the degree to which the caregiver was adherent overall with homework immediately after each session on a scale of 1 (not at all) to 5 (extremely strong).
|
During the 9-week treatment
|
|
The Client Credibility Questionnaire
Time Frame: Immediately post-treatment
|
4 item questionnaire to determine how logical and successful the treatment is; if they would recommend the intervention to others; and how much symptoms improved.
|
Immediately post-treatment
|
|
Parenting Sense of Competence Scale
Time Frame: Baseline, immediately post-treatment, 3 months post-treatment
|
A 17-item questionnaire with a 6-point Likert Scale ranging from Strongly Disagree (1) to Strongly Agree (6).
A higher score indicates a higher parenting sense of competency.
|
Baseline, immediately post-treatment, 3 months post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jessica Lunsford-Avery, PhD, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 24, 2023
Primary Completion (Actual)
January 30, 2026
Study Completion (Actual)
January 30, 2026
Study Registration Dates
First Submitted
April 3, 2023
First Submitted That Met QC Criteria
May 8, 2023
First Posted (Actual)
May 17, 2023
Study Record Updates
Last Update Posted (Actual)
February 4, 2026
Last Update Submitted That Met QC Criteria
February 2, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00111845
- R34MH131994-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All of the individual participant data collected during the trial (including data dictionaries) will be available for this study after deidentification.
IPD Sharing Time Frame
Immediately following publication.
No end date.
IPD Sharing Access Criteria
Data will be accessible by researchers who provide a methodologically sound proposal to achieve aims in the approved proposal.
Proposals and questions for data access should be directed to NDAHelp@mail.nih.gov.
To gain access, data requestors will need to sign a data access agreement at https://nda.nih.gov/nda/access-data-info.html.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
St. Antonius HospitalNot yet recruitingADHD | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD, Predominantly Hyperactive - Impulsive | Attention Deficit Disorder (ADD) | Hyperactivity | Inattention | ADHD Predominantly Hyperactivity Type | ADHD-not Other Specified | Hyperactivity... and other conditions
-
Wuhan Sports UniversityTerminatedADHD | ADHD - Combined Type | ADHD - Inattentive Type | ADHD - Attention Deficit Disorder With Hyperactivity | ADHD Specifically With Executive Function ImpairmentChina
-
The Hong Kong Polytechnic UniversityRecruiting
-
Loewenstein HospitalWingate InstituteRecruiting
-
Region Örebro CountyActive, not recruiting
-
University of TorontoCompleted
-
Massachusetts General HospitalCenter for Survey Research, University of Massachusetts, BostonCompleted
-
Akili Interactive Labs, Inc.Active, not recruiting
-
L'hôpital Nord-Ouest - Villefranche Villefranche...Completed
-
Johns Hopkins UniversityWithdrawn
Clinical Trials on Telehealth Intervention
-
VA Boston Healthcare SystemSamueli Institute for Information BiologyCompletedPost Traumatic Stress DisordersUnited States
-
Vanderbilt University Medical CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedChronic Low-back Pain | Postsurgical Pain | Lumbar Spine SurgeryUnited States
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingProlapse | IncontinenceUnited States
-
University of California, Los AngelesPatient-Centered Outcomes Research InstituteCompletedDepression | Anxiety | Developmental Delay | Autism | Behavioral Problems | Adhd | Developmental, Behavioral and Mental HealthUnited States
-
Boston Children's HospitalCompleted
-
Georgetown UniversityRecruitingCancer | Periodontal Diseases | Oral MucositisUnited States
-
University of British ColumbiaVancouver Coastal Health Research InstituteNot yet recruitingQuality of Life | Medication Adherence | Asthma ExacerbationCanada
-
Duke UniversityCompletedHypertension | Diabetes | Diabetic Kidney DiseaseUnited States
-
South Florida Veterans Affairs Foundation for Research...UnknownDiabetes | Pre-diabetesUnited States
-
Indiana UniversityCompletedChildhood ObesityUnited States